// App-Quantinova.ai

2034 : Lipopolysaccharide increases the release of CXCL5 in an ex‐vivo model for human non‐alcoholic fatty liver disease

Researchers

Presenter

  • Olivier Govaere

Principal Investigators

  • Lee H. Reed

  • Simon J. Cockell

  • Jeremy J. French

  • Steven A. White

  • Derek Manas

  • Ann K. Daly

  • Stuart M. Robinson

  • Lee Borthwick

  • Michael J. Drinnan

  • Dina Tiniakos

  • Quentin M. Anstee

  • Fiona Oakley

Medical Centers

  • Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom

  • Bioinformatics Unit, Newcastle University, Newcastle-upon-Tyne, United Kingdom

  • Department of Biochemistry, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

  • Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Fatty Liver Disease

  • Colorectal Cancer

  • Solid malignancies

Biomarkers

  • C-X-C motif chemokine ligand 5

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved